medtrace logo

[O-15]-H2O is the gold standard for quantifying blood flow We are making it available for routine use

Higher Accuracy

Optimal kinetics allow application in most organs

Improved Efficiency

Higher patient throughput and no 3rd party dependencies (in-house production)

Better Safety

Lowest radiation exposure to patients and staff

Vision

MedTrace was founded with the belief that we can improve diagnostic accuracy in PET perfusion examinations. Our first ambition has been to focus on cardiac diseases, and to make [O-15]-H2O practically available. We want doctors around the globe to have access to the gold standard perfusion tracer which is [O-15] H2O and to help usher in a new era in diagnostic medicine.

OUR TECHNOLOGY


MedTrace develops a novel solution consisting of a hardware device and automated analytical software which combined will revolutionize blood flow imaging in PET

The software solution – aQuant – is a unique analytical platform under development to interpret the [O-15]-H2O PET scans. With the aQuant analysis software, MedTrace is developing the world’s first scanner independent, regulatory approved software offering absolute quantification. Compared to the early days of [O-15] – H2O research, aQuant offers clear visual interpretation along with quantitative data of absolute blood flow.

The hardware part of the solution is the MT-100 (under development) that automates bedside production and infusion of [O-15]-H2O in the PET scanner suite – just in time for medical demands. The MT-100 will be the world’s first self shielded, GMP-compliant chemistry system for automated production and injection of [O-15] – H2O. End of Synthesis is (EoS) is >27 mCi/ml (1G Bq/ml)

The MedTrace solution is a platform technology. Our first priority is the heart study application (myocardial perfusion imaging), with tumor and brain vascularization studies as well as diabetes applications under development

Pathway to market

MedTrace is currently preparing for a pivotal Phase III clinical trial evaluating [O-15] H2O PET scans towards invasive coronary angiogram and current best practice SPECT scans. The trial will be conducted under FDA approval and include patients from EU, US and Japan. Several US hospitals are involved coast-to-coast accompanied by three European hospitals and one Japanese.

“The flow of water through the tissues is essentially what makes life possible. All diseases affect the flow of water one way or another. This opens up powerful opportunities of diagnosis using [O-15] – H2O water and PET”

Professor Jens Soerensen MD PhD, PET Centre, Uppsala University Hospital, Sweden

CLINICAL BENEFITS


REVOLUTIONIZE BLOOD FLOW IMAGING IN PET

Currently, routine myocardial perfusion exams are performed with Tc-99m, Rb-82 and 13N-NH3. The globally recognized gold standard tracer for absolute blood flow measurements is [O-15]-H2O (radioactive water), which is used in many clinical studies as the benchmark. The short half-life of radioactive water, the difficult analysis as well as lack of regulatory approved equipment has limited its use in clinical practice so far. With MedTrace’s solution of hardware and analytical software, doctors all over the world will get clinical access to routine use of [O-15]-H2O.

THIS WILL ALLOW

Access to gold standard tracer ([O-15]-H2O) for routine blood flow exams
Faster patient turnaround (2-3 double-tests/hour)
Increased safety for patients and staff
In-house production of the tracer- no 3rd party logistics dependencies

Cardiology
Gold standard for myocardial perfusion

Oncology
Tumor microvasculature

Diabetes
Diabetic foot

Neurology  
Functional bloodflow – Apoplexy, Alzheimer’s

Clinical physiology
Organ blood supply

Tissue perfusion
Ischemic muscle, collateral blood supply

Oncology
Tumor microvasculature.
Neurology
Blood flow to selected brain domains, incl. quantification of apoplexy, alzheimer, dementia, schizophrenia etc.
Diabetes
Diabetec foot.
Cardiology
Myocardial perfusion – the gold standard.
Clinical Physiology
General organ specific blood perfusion, for organ functionality assessment.
Tissue perfusion
Ischemic muscle, collateral blood supply.

ABOUT MEDTRACE


OUR STORY

We are a development stage company innovating PET diagnostic imaging. Having experienced the challenges with false results in myocardial blood flow imaging, we are determined to make the blood flow tracer [O-15]-H2O (radioactive water) practically available for clinical use allowing doctors to use the gold standard in the clinic.

OUR PARTNERS

MedTrace collaborates with university hospitals in the US, Europe and Japan as well as global industry partners within nuclear medicine. We are continuously looking for interested clinical, technological and commercial partners globally.

“The availability of a reliable CE approved system for bed-side production of O-15 water could change O-15 water PET from an exotic research tool to a clinical workhorse”

Physicist Lars Poulsen Tolbod, Aarhus University Hospital, Denmark

OUR TEAM


Martin Stenfeldt

Martin Stenfeldt

CEO

Rune Wiik Kristensen

Rune Wiik Kristensen

Chief Operational Officer

Jens Soerensen, MD, Professor

Jens Soerensen, MD, Professor

Chief Medical Officer

Mark Lubberink, Professor

Mark Lubberink, Professor

Chief Scientific Officer

Peter Larsen, PhD

Peter Larsen, PhD

EVP, Hardware Development

Hans Harms, PhD

Hans Harms, PhD

VP, Software Development

Lars Poulsen Tolbod

Lars Poulsen Tolbod

VP New Indications

Kasper Lykkegaard Therkelsen

Kasper Lykkegaard Therkelsen

Usability and Engineering

Janine Sauer

Janine Sauer

Intern, Regulatory Affairs

Therese Eilskov Lundmark Jensen

Therese Eilskov Lundmark Jensen

Student Assistant – Legal Affairs

Naba Houssein

Naba Houssein

Student Assistant, Medical Affairs

OUR BOARD OF DIRECTORS


Ulrik Spork

Ulrik Spork

Chairman, Medtrace A/S

Bernt Skou Jensen

Bernt Skou Jensen

Member of the board, MedTrace A/S

Mads Rasmussen

Mads Rasmussen

Vice-chairman, MedTrace A/S

Jens Soerensen, MD, Professor

Jens Soerensen, MD, Professor

Chief Medical Officer

Michael Frank

Michael Frank

Member of the board, MedTrace A/S

OUR MENTORS


MedTrace receives mentoring from two group-mentoring programs; Futurebox and NOME. Learn more by clicking on the logos below.



OUR INVESTORS




GRANTS AND AWARDS


DTC Award

We are confident that the introduction of the MedTrace solution will be a paradigm shift in diagnostic imaging impacting most known disease areas.

Rune Wiik Kristensen, CSO, MedTrace A/S

REFERENCES


MEDIA

TECHNOLOGY

SCIENTIFIC


We believe that making [O-15]-H2O practically available for clinical use will change the world of perfusion exams.

Want to stay in contact and follow our journey? follow MedTrace on Facebook, LinkedIn and Twitter.

HQ | MedTrace A/S

Gotlandsvej 5
DK-5700 Svendborg

R&D | MedTrace A/S

Diplomvej 381
DK-2800 Lyngby

Swedish Office | MedTrace AB

Hågavägen 322
S-75263 Uppsala

US Office | MedTrace Pharma, Inc.

545 Boylston Street
Boston, MA-02116